Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
1d
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
6d
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.
Hosted on MSN6d
What's Behind the Insider Buying on This High-Yield Stock?New Jersey-based Bristol-Myers Squibb Company (BMY) stands out as a global ... And more recently making headlines is Cobenfy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback